{"id":52992,"date":"2024-11-20T13:13:49","date_gmt":"2024-11-20T13:13:49","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?post_type=partner&p=52992"},"modified":"2025-01-13T13:57:03","modified_gmt":"2025-01-13T13:57:03","slug":"vaccine-development-to-combat-bacterial-infections-and-amr","status":"publish","type":"partner","link":"https:\/\/www.innovationnewsnetwork.com\/partner\/vaccine-development-to-combat-bacterial-infections-and-amr\/","title":{"rendered":"Sequoia Vaccines: Pioneering vaccine development to combat bacterial infections and AMR"},"content":{"rendered":"
This clinical-stage company is dedicated to tackling bacterial infections, pioneering solutions for antimicrobial resistance, and addressing other critical health challenges, including cancer and cystic fibrosis-related lung infections. With a mission to transform patient care, Sequoia Vaccines harnesses cutting-edge science and nature-inspired technology to develop novel compounds and therapies.<\/p>\n
Sequoia Vaccines\u2019 success is guided by a leadership team with over a century of collective expertise in pharmaceutical research and development. This wealth of knowledge drives every stage of the process, from early discovery to global commercialisation.<\/p>\n
Central to Sequoia\u2019s methodology is the integration of advanced plant-based technologies. The company utilises state-of-the-art purification techniques to explore the vast potential of botanical compounds.<\/p>\n
A partnership with the Missouri Botanical Garden enabled access to a diverse array of plant species, leading to the discovery of unique chemical scaffolds.<\/p>\n
These breakthroughs set the stage for its ambitious efforts to combat bacterial infections, reduce antibiotic dependence, and develop cancer therapies. The early success of these programmes catalysed the launch of Sequoia\u2019s vaccine research and development programme.<\/p>\n
Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi, and parasites evolve to withstand the effects of antibiotics, antivirals, and antifungals, rendering these treatments ineffective. This phenomenon is fueled by the overuse and misuse of antibiotics and has become a major global health crisis.<\/p>\n
The consequences of AMR are severe, including prolonged illnesses, higher medical costs, and increased mortality rates. Urgent action is needed to reduce antibiotic use and develop alternative strategies, such as vaccines, to prevent bacterial infections and slow the spread of resistance.<\/p>\n
Sequoia Vaccines is committed to addressing AMR by developing vaccines that reduce reliance on antibiotics. By focusing on prevention, Sequoia contributes to global efforts to curb the rise of multidrug-resistant bacteria.<\/p>\n
Their research aligns with initiatives like the U.S. Centers for Disease Control and Prevention\u2019s (CDC) Antimicrobial Resistance Challenge, which emphasises innovation in vaccine development.<\/p>\n